兆科眼科旗下用于治疗老花眼的药物Yuvezzitm,已正式获得澳门特别行政区政府药物监督管理局的上市批准。这一监管进展标志着该产品在特定市场迈出了商业化的重要一步,为相关患者群体提供了新的治疗选择。
兆科眼科旗下用于治疗老花眼的药物Yuvezzitm,已正式获得澳门特别行政区政府药物监督管理局的上市批准。这一监管进展标志着该产品在特定市场迈出了商业化的重要一步,为相关患者群体提供了新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.